MSA
NVO

Marino Stram & Associates’s Novo Nordisk NVO Stock Holding History

Marino Stram & Associates’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-1,034
Closed -$27K – 408
2019
Q1 		$27K Hold
1,034
– – 0.02% 214
2018
Q4 		$24K Buy
1,034
+34
+3% +$756 0.02% 198
2018
Q3 		$24K Buy
+1,000
New +$24.4K 0.02% 227

Other funds holding NVO

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fayez Sarofim & Co
Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
State Farm Mutual Automobile Insurance
State Farm Mutual Automobile Insurance Bloomington, Illinois $127B AUM 32.55% 1-Year Est. Return

Marino Stram & Associates's NVO Position: Q2 2019 in Review

Marino Stram & Associates sold out of Novo Nordisk (NVO) in Q2 2019, closing a stake of 1,034 shares — an estimated $27K sold.

Marino Stram & Associates first reported a position in NVO in Q3 2018 and held it in 3 quarters. The position peaked at $27K in Q1 2019. 559 funds tracked by Wall St. Rank hold NVO as of Q2 2019.

  • Marino Stram & Associates reported no remaining Novo Nordisk position as of Q2 2019 after selling out during the quarter.
  • Marino Stram & Associates sold 1,034 Novo Nordisk shares in Q2 2019, an estimated $27K.
  • Marino Stram & Associates first reported a position in Novo Nordisk in Q3 2018 and held it in 3 quarters.
  • Marino Stram & Associates's Novo Nordisk position peaked at $27K in Q1 2019.
  • 559 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2019.

Based on Marino Stram & Associates's 13F filing for Q2 2019, filed 19 Jul 2019.